Ian Miller

6PUBLICATIONS
13CO-AUTHORS
Autonomic nervous systemCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsBiologically active moleculesDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 20, 2022
A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.

Pasquale Striano, Stéphane Auvin, Abigail Collins

|Feb 17, 2022
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6.

Joyce Y Wu, Hannah R Cock, Orrin Devinsky

|Aug 21, 2021
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.

James W Wheless, Ian Miller, R Edward Hogan

|Aug 18, 2021
Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial.

Ingrid E Scheffer, Jonathan J Halford, Ian Miller

|May 25, 2021
Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study.

Ian Miller, James W Wheless, Robert E Hogan

|May 04, 2021
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study.

Eric B Segal, Daniel Tarquinio, Ian Miller

Pageof 1

Frequent Collaborators

3 joint publications

Robert E Hogan

3 joint publications

Michael R Sperling

2 joint publications

Ingrid E Scheffer

2 joint publications

Rocio Sanchez-Carpintero